Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

被引：64

作者：

Frost, Jeffrey L. ^{[1
]}

Liu, Bin ^{[1
]}

Kleinschmidt, Martin ^{[2
]}

Schilling, Stephan ^{[2
]}

Demuth, Hans-Ulrich ^{[2
]}

Lemere, Cynthia A. ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA

[2] Probiodrug AG, Halle, Saale, Germany

来源：

NEURODEGENERATIVE DISEASES | 2012年 / 10卷 / 1-4期

关键词：

Alzheimer's disease; Pyroglutamate-3; amyloid-beta; Monoclonal antibody; Immunotherapy; Transgenic mice; A-BETA; DISEASE; DEPOSITION; PEPTIDES; MUTATION;

D O I：

10.1159/000335913

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: N-terminally truncated and modified pyroglutamate-3 amyloid-beta protein (pE3-A beta) is present in most, if not all, cerebral plaque and vascular amyloid deposits in human Alzheimer's disease (AD). pE3-A beta deposition is also found in AD-like transgenic (tg) mouse brain, albeit in lesser quantities than general A beta. pE3-A beta resists degradation, is neurotoxic, and may act as a seed for A beta aggregation. Objective: We sought to determine if pE3-A beta removal by passive immunization with a highly specific monoclonal antibody (mAb) impacts pathogenesis in a mouse model of Alzheimer's amyloidosis. Methods: APPswe/PS1 Delta E9 tg mice were given weekly intraperitoneal injections of a new anti-pE3-A beta mAb (mAb07/1) or PBS from 5.8 to 13.8 months of age (prevention) or from 23 to 24.7 months of age (therapeutic). Multiple forms of cerebral A beta were quantified pathologically and biochemically. Gliosis and microhemorrhage were examined. Results: Chronic passive immunization with an anti-pE3-A beta mAb significantly reduced total plaque deposition and appeared to lower gliosis in the hippocampus and cerebellum in both the prevention and therapeutic studies. Insoluble A beta levels in hemibrain homogenates were not significantly different between immunized and control mice. Microhemorrhage was not observed with anti-pE3-A beta immunotherapy. Conclusions: Selective removal of pE3-A beta lowered general A beta plaque deposition suggesting a pro-aggregation or seeding role for pE3-A beta. Copyright (C) 2012 S. Karger AG, Basel

引用

页码：265 / 270

页数：6

共 20 条

[1] Amyloidogenic processing of amyloid precursor protein:: Evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-β [J].

Cynis, Holger ;

Scheel, Eike ;

Saido, Takaomi C. ;

Schilling, Stephan ;

Demuth, Hans-Ulrich .

BIOCHEMISTRY, 2008, 47 (28) :7405-7413

[2] Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease [J].

Garcia-Alloza, Monica ;

Robbins, Elissa M. ;

Zhang-Nunes, Sandy X. ;

Purcell, Susan M. ;

Betensky, Rebecca A. ;

Raju, Susan ;

Prada, Claudia ;

Greenberg, Steven M. ;

Bacskai, Brian J. ;

Frosch, Matthew P. .

NEUROBIOLOGY OF DISEASE, 2006, 24 (03) :516-524

[3] High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain [J].

Guentert, A. ;

Doebeli, H. ;

Bohrmann, B. .

NEUROSCIENCE, 2006, 143 (02) :461-475

[4] The Aβ 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β-sheet forming and aggregation propensities in vitro than full-length Aβ [J].

He, WL ;

Barrow, CJ .

BIOCHEMISTRY, 1999, 38 (33) :10871-10877

[5] Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo:: evidence for augmentation of a 42-specific γ secretase [J].

Jankowsky, JL ;

Fadale, DJ ;

Anderson, J ;

Xu, GM ;

Gonzales, V ;

Jenkins, NA ;

Copeland, NG ;

Lee, MK ;

Younkin, LH ;

Wagner, SL ;

Younkin, SG ;

Borchelt, DR .

HUMAN MOLECULAR GENETICS, 2004, 13 (02) :159-170

[6] Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation [J].

Lemere, CA ;

Blusztajn, JK ;

Yamaguchi, H ;

Wisniewski, T ;

Saido, TC ;

Selkoe, DJ .

NEUROBIOLOGY OF DISEASE, 1996, 3 (01) :16-32

[7] Intranasal immunotherapy for the treatment of Alzheimer's disease:: Escherichia coli LT and LT(R192G) as mucosal adjuvants [J].

Lemere, CA ;

Spooner, ET ;

Leverone, JF ;

Mori, C ;

Clements, JD .

NEUROBIOLOGY OF AGING, 2002, 23 (06) :991-1000

[8] The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology [J].

Lemere, CA ;

Lopera, F ;

Kosik, KS ;

Lendon, CL ;

Ossa, J ;

Saido, TC ;

Yamaguchi, H ;

Ruiz, A ;

Martinez, A ;

Madrigal, L ;

Hincapie, L ;

Arango, JCL ;

Anthony, DC ;

Koo, EH ;

Goate, AM ;

Selkoe, DJ ;

Arango, JCV .

NATURE MEDICINE, 1996, 2 (10) :1146-1150

[9] Amino-terminally truncated Aβ peptide species are the main component of cotton wool plaques [J].

Miravalle, L ;

Calero, M ;

Takao, M ;

Roher, AE ;

Ghetti, B ;

Vidal, R .

BIOCHEMISTRY, 2005, 44 (32) :10810-10821

[10] β-amyloid is different in normal aging and in Alzheimer disease [J].

Piccini, A ;

Russo, C ;

Gliozzi, A ;

Relini, A ;

Vitali, A ;

Borghi, R ;

Giliberto, L ;

Armirotti, A ;

D'Arrigo, C ;

Bachi, A ;

Cattaneo, A ;

Canale, C ;

Torrassa, S ;

Saido, TC ;

Markesbery, W ;

Gambetti, P ;

Tabaton, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (40) :34186-34192

← 1 2 →